Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
Saved in:
| Title: | Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. |
|---|---|
| Authors: | Al Rabadi LS; Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Road, OC14HO, Portland, OR, 97239, USA., Cook MM; School of Medicine, Oregon Health & Science University, Portland, OR, USA., Kaempf AJ; Knight Cancer Institute, Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR, USA., Saraceni MM; Department of Pharmacy, Oregon Health & Science University, Portland, OR, USA., Savin MA; Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Road, OC14HO, Portland, OR, 97239, USA., Mitri ZI; Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Road, OC14HO, Portland, OR, 97239, USA. mitri@ohsu.edu. |
| Source: | BMC cancer [BMC Cancer] 2021 Oct 27; Vol. 21 (1), pp. 1150. Date of Electronic Publication: 2021 Oct 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-021-08894-2 |
